Accelerated Approval allows for early access to drugs and biologics based on initial evidence of safety and effectiveness, while confirmatory studies required to verify clinical benefits are ongoing. Do patients care? No.
The promise of one-stop, total healthcare was supposed to be led by retailers like Wal*Mart and CVS, but they’re finding out it costs a lot of money to equip and market these facilities. Patients still want convenience in their healthcare, but it may take decades to materialize.
An increasing number of headlines amplifying many incomplete data around telehealth have led industry stakeholders to extrapolate discrete data points about telehealth to the entire U.S. population. Using an economic framework to analyze national telehealth data. Only 25.6% of Americans utilized telehealth during the two years of the pandemic. Said another way, investments in the telehealth market have been made on the thesis that telehealth is preferred among most Americans. But the reality is that all these efforts are being dedicated to only a subset of the U.S. population. (Source: Trilliant Health Feb 2022)
I admire President Biden for trying for a cancer cure moonshot but unfortunately, cancer is not just one disease; it’s many with a range of different causes, physiologies, and treatments. What treatment works in one patient may not work in another but we have to keep trying to beat cancer anyway we can.
The pharma industry’s reputation continues to slip from a pandemic halo-high of 62% in February 2021 to now when fewer than half, just 47%, of people have a favorable view of the industry, according to the Harris Poll’s latest survey. (Source: Endpoints News) Does anyone believe that pharma cares?
Although reported COVID-19 deaths between Jan 1, 2020, and Dec 31, 2021, totaled 5·94 million worldwide, we estimate that 18·2 million (95% uncertainty interval 17·1–19·6) people died worldwide because of the COVID-19 pandemic (as measured by excess mortality) over that period. (Source: The Lancet). Overt politicization of the pandemic—and the speed with which falsehoods about all aspects of COVID-19 have spread online, over the airwaves, and through media—are significant reasons why the U.S. has suffered a far greater COVID-related death toll than other large, well-resourced nations.
It’s not only getting harder for small biotechs to find funding; too many have scaled up operations by adding employees too quickly, forcing them to lay off people as the path to new drug approvals gets more complicated.
After two years of pandemic fatigue, healthcare trust is at an all-time low, according to Edelman’s Trust Barometer Special Report on Trust in Healthcare. Still, the report may be too generalized for every healthcare player.